Glaucoma Clinical Trial
Official title:
Evaluation of New Head-mounted Visual Aids Among Patients With Low Vision
Glaucoma, age-related macular degeneration (AMD), retinitis pigmentosa, RP, diabetic retinopathy (DR) are the most common blinding eye diseases in the world. Vision and visual field are often severely impaired, quality of life is reduced, and personal and family burdens are heavy. This kind of low vision people, can use visual AIDS and other instruments for visual rehabilitation training, maximize the function of residual vision, improve the quality of life. Beyes, HOLA, Acesight and OXSIGHT are among the latest eyeglasses devices that are expected to improve the quality of life for people with low vision. This research group intends to recruit advanced patients with primary glaucoma, AMD, RP, DR and other common blinding eye diseases who visited Zhongshan Ophthalmology Center of Sun Yat-sen University from June 2021 to December 2022 to study the changes of visual function and quality of life after wearing this new type of head-worn visual aids, and analyze relevant factors combined with clinical data. To evaluate the effect and influencing factors of the new head-mounted visual AIDS on patients, and provide theoretical basis for subsequent clinical research.
1. Low vision Low visual acuity refers to a patient who has functional impairment of vision even after treatment or standard refractive correction. The visual acuity of the good middle eye in both eyes is less than 0.3, or the field radius is ≤20°, but still has the ability to use the remaining vision to perform a certain visual activity. In China, low vision caused by eye diseases (such as glaucoma, AMD, RP, DR) can lead to behavioral loss of patients, and standardized rehabilitation treatment of low vision can help 90% of visual impairment patients improve the utilization rate of residual vision, becoming an important way to compensate for the loss of visual function of this group. 2. Visual rehabilitation of low vision The latest definition of visual rehabilitation is a kind of multidisciplinary comprehensive rehabilitation therapy. By ophthalmologists, depending on the light, low vision devices, low vision rehabilitation counselors professional therapists, social workers and psychologists of the multidisciplinary team, using physical, audio, electronic, optical instruments, and life skills training, help patients with low vision to use its residual vision and development skills available to offset the impact of visual impairment in patients, To improve their self-living ability and quality of life. There are three treatment levels: discovery, guidance and referral; Individual rehabilitation; Multidisciplinary visual rehabilitation. The first step of visual rehabilitation is often accurate optometry in order to obtain the best corrected vision, which is also an important basis for the success of visual rehabilitation. On the basis of refractive correction, it can obviously improve the daily living ability and quality of life of the patients with low vision by providing them with appropriate visual aids and corresponding training of using visual aids. Visual aids are generally divided into near-use and far-use visual aids, in which near-vision and reading ability are the focus of functional vision assessment and rehabilitation. Traditional used visual aids have hand-held magnifier, vertical magnifier, glasses and electronic visual aids. Compared with optical visual aids, electronic visual aids have the advantages of clear imaging, adjustable magnification and contrast. 3. Research status of smart wearable devices Traditional visual AIDS achieve the effect of object image amplification through the principle of optics, but have fixed magnification rate, reduced field of vision, small depth of field, short working distance, can not adjust the contrast and other shortcomings. In recent years, video wearable devices have been gradually applied in the field of visual rehabilitation, with the advantages of adjustable magnification, adjustable contrast and high clarity, overcoming the limitations of traditional optical devices, including eSight 3, NuEyes, IrisVision, etc. Currently, there are few studies on wearable electronic visual aids. Walter Wittich et al. conducted an intervention trial on 51 patients with low vision and confirmed that wearable electronic visual aids can improve patients' visual acuity, spatial object recognition ability, and reading and activity ability. In the study of middle-advanced glaucoma, Yogesh Patodia et al. found that wearable electronic visual aids can also improve their long-range and near-range vision. Smart glasses such as Beyes, HOLA, Acesight and OXSIGHT are the latest wearable electronic visual aids to hit the market, featuring advantages of lighter weight, comfortable wearing, better imaging quality and multi-mode assisted visual recognition. However, the effect and influencing factors of this kind of smart glasses on advanced patients with glaucoma, AMD, RP, DR and other common blinding eye diseases are still unclear, which requires further exploration by researchers. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A |